Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T17:07:10.981Z.
Calculation as of: 2026-10-06T17:07:10.981Z.
Quote observation: 2026-10-06T17:03:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 451a64ce4da380df6ab4c5027584c6fd3c25ecc0cb3c19eab7daced69cd0f5b9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$34.97M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$34.10M
EV/Sales Ratio
0.44x
TTM Avg
0.48x
3Y Avg
0.66x
5Y Avg
0.78x
Market Cap
$35.42M
EV/Sales Ratio
1.02x
TTM Avg
7.17x
3Y Avg
30.29x
5Y Avg
30.29x
Market Cap
$33.66M
EV/Sales Ratio
0.22x
TTM Avg
15.56x
3Y Avg
19.81x
5Y Avg
321.73x
Market Cap
$33.24M
EV/Sales Ratio
3.00x
TTM Avg
7.33x
3Y Avg
18.71x
5Y Avg
16.11x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $34.58M | N/A | N/A | N/A | N/A |
| Elutia Inc (ELUT)vs › | $34.76M | 2.11x | 1.98x | 3.00x | 2.66x |
| BriaCell Therapeutics Corp. (BCTX)vs › | $34.97M | N/A | N/A | N/A | N/A |
| Accuray Incorporated (ARAY)vs › | $34.10M | 0.44x | 0.48x | 0.66x | 0.78x |
| QT Imaging Holdings, Inc. (QTI)vs › | $35.42M | 1.02x | 7.17x | 30.29x | 30.29x |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.66M | 0.22x | 15.56x | 19.81x | 321.73x |
| DocGo Inc. (DCGO)vs › | $35.81M | 0.12x | 0.15x | 0.42x | 1.17x |
| HeartBeam, Inc. (BEAT)vs › | $33.25M | N/A | N/A | N/A | N/A |
| EUDA Health Holdings Limited (EUDA)vs › | $33.24M | 3.00x | 7.33x | 18.71x | 16.11x |
| Scilex Holding Company (SCLX)vs › | $32.50M | 4.03x | 4.11x | 4.50x | 18.25x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
